Avalo Therapeutics
AVTX
65 hedge funds and large institutions have $56.2M invested in Avalo Therapeutics in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 25 reducing their positions, and 14 closing their positions.
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
7% less funds holding
Funds holding: 70 → 65 (-5)
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
50% less call options, than puts
Call options by funds: $6K | Put options by funds: $12K
56% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 25
59% less capital invested
Capital invested by funds: $136M → $56.2M (-$79.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2.25M |
| 2 |
Renaissance Technologies
New York
|
+$284K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$62.8K |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$37.7K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$30.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.57M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$1.31M |
| 3 |
IHAM
Integral Health Asset Management
New York
|
-$806K |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$470K |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$259K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ECM
76
ExodusPoint Capital Management
New York
| – | -$18K | -4 | Closed |
|
77
Principal Financial Group
Des Moines,
Iowa
| – | -$18K | -4 | Closed |
|
78
SG Americas Securities
New York
| – | -$17K | -4 | Closed |
|
|
XT
79
XTX Topco
George Town,
Cayman Islands
| – | -$20K | -4 | Closed |
|
AVTX Hedge Fund Activity: Q1 2022 in Review
65 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q1 2022, worth a combined $56.2M — down 59% from $136M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of AVTX and 9 opened new positions — a net loss of 5 holders — while 25 trimmed existing stakes and 11 added.
The largest buyer was Armistice Capital, adding an estimated $2.25M. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $2.57M sold.
- 65 institutional investors held Avalo Therapeutics (AVTX) as of Q1 2022, down from 70 in Q4 2021.
- Funds reported $56.2M of Avalo Therapeutics stock for Q1 2022, down 59% quarter-over-quarter.
- 9 funds opened new Avalo Therapeutics positions in Q1 2022 and 14 closed out, a net change of -5 holders.
- The largest Avalo Therapeutics buyer in Q1 2022 was Armistice Capital, an estimated $2.25M added.
- The largest Avalo Therapeutics seller in Q1 2022 was Stonepine Capital Management, an estimated $2.57M sold.
Based on aggregated 13F filings for Q1 2022.